Tue. Oct 26th, 2021

endpoint

The MarketWatch News Department was not involved in the creation of this content.

Dec 02, 2020 (CDN Newswire via Comtex) —
Global Master Data Management PDS Software Market 2020 by Company, Type and Application, Forecast to 2025 contains point by point data which enlarge understanding, scope, and application of this market. The report provides an in-depth analysis of industry- and economy-wide database that could offer development and profitability for players in this global Master Data Management PDS Software market. The report divided by producers, regions, applications, and types provides information based on portfolio, applications, cost, producing processes. The report covers market trends, future advancement extension, and industry growth analysis. It presents analysis and insights regarding the various factors expected to be prevalent throughout the forecasted period (2020-2025). Then perspective on specific organizations, associations, manufacturers, industries, companies, and suppliers that are working to expand their business worldwide has been offered. Analysis

Read More ... Read More

The MarketWatch News Department was not involved in the creation of this content.

Nov 23, 2020 (GLOBE NEWSWIRE via COMTEX) —
Oxford Biomedica notes AstraZeneca’s AZD1222 met primary efficacy endpoint in preventing COVID-19


Oxford, UK – 23 November, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, notes AstraZeneca PLC (“AstraZeneca”) announced AZD1222 met primary efficacy endpoint in preventing COVID-19.

Key highlights from the announcement were as follows:

  • Two different dosing regimens demonstrated efficacy with one showing a better profile
  • No hospitalisations or severe cases of COVID-19 in participants treated with AZD1222
  • One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose followed by a full dose at least one month apart, and another dosing regimen (n=8,895) showed 62% efficacy when given two full doses at least one month apart
  • No serious safety events related
Read More ... Read More